Washington University in Saint Louis
Welcome,         Profile    Billing    Logout  
 73 Trials 
76 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Connolly, Anne
EMERGENE, NCT06246513: A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Recruiting
3
15
Europe, US
SRP-9003, scAAVrh74.MHCK7.hSGCB, bidridistrogene xeboparvovec, Glucocorticoid, Prednisone or equivalent
Sarepta Therapeutics, Inc.
Limb-girdle Muscular Dystrophy
01/25
11/29
Ewald, Gregory A
MUSIC-HFrEF1, NCT04703842: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Recruiting
1/2
57
US
SRD-001, Placebo
Sardocor Corp., Covance
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
12/25
12/28
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Completed
1
44
Japan, US
LY3461767, Placebo
Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
05/24
05/24
Tine, Brian Van
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated
2
3
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells
Adaptimmune, ICON plc
Esophageal Cancer, Esophagogastric Junction Cancer
06/23
12/23
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT04551430: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting
2
105
US
Cabozantinib, Nivolumab, Opdivo, Ipilimumab, Yervoy
Washington University School of Medicine, Exelixis, Bristol-Myers Squibb
Metastatic Soft-tissue Sarcoma
06/24
06/30
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
02/27
09/28
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCT04887298: Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

Completed
1/2
36
US
Liposomal Annamycin (L-Annamycin)
Moleculin Biotech, Inc.
Sarcoma,Soft Tissue, Pulmonary Metastasis
09/22
08/24
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting
1/2
48
US, RoW
Vactosertib, TEW-7197
MedPacto, Inc.
Osteosarcoma
07/25
11/25
NCT05813327: Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Recruiting
1/2
35
US
ADI PEG20, PEGylated arginine deiminase, Ifosfamide, ifex, Radiotherapy, Mesna, sodium 2-mercaptoethane sulfonate
Washington University School of Medicine, Polaris Group
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
01/26
01/28
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
NCT05616624: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Recruiting
1/2
114
US
ADI-PEG 20, PEGylated arginine deiminase, Gemcitabine, Gemzar, Docetaxel, Taxotere
Washington University School of Medicine, Polaris Group
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
12/27
12/32
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
SURPASS, NCT04044859: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Checkmark Results from SURPASS trial for MAGE-4 positive tumors
Sep 2022 - Sep 2022: Results from SURPASS trial for MAGE-4 positive tumors
Checkmark Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Nov 2019 - Nov 2019: Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Recruiting
1
120
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Adaptimmune, ICON plc
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
12/25
04/37
NCT03761095: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Completed
1
41
US
Unesbulin, PTC596, Dacarbazine, DTIC
PTC Therapeutics
Leiomyosarcoma
02/24
02/24
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1
49
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
INDP-D101, NCT05651022: DECOY20 Study in Patients with Advanced Solid Tumors

Recruiting
1
120
US
Decoy20
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult
06/27
09/27
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
Bateman, Randall
DIAN-TU, NCT06384573: Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Recruiting
3
65
Europe, US, RoW
lecanemab, BAN2401
Washington University School of Medicine, Alzheimer's Association, Eisai Inc.
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
11/29
11/29
DIAN-TU, NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Terminated
2/3
73
Europe, US, RoW
Gantenerumab, RO4909832
Washington University School of Medicine, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
10/23
11/23
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
Conway, Charles R
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Haroutounian, Simon
EPIPHANY, NCT03997981: Chemotherapy Induced Peripheral Neuropathy Natural History Study

Recruiting
N/A
200
US
Disarm Therapeutics, Eli Lilly and Company
Chemotherapy-induced Peripheral Neuropathy
03/24
04/24
Lasala, John
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Mueller, Sabine
NCT01734512: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Completed
2
65
US
Everolimus
University of California, San Francisco, Novartis Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium, The Pediatric Low Grade Astrocytoma (PLGA) Foundation
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
01/20
07/24
NCT05123534: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

Suspended
2
15
US
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS), Exablate Type 2.0
SonALAsense, Inc.
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
07/24
10/24
PNOC029, NCT05465174: Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
56
US
Nivolumab, Opdivo, Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Bristol-Myers Squibb, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
NCT03690869 / 2023-000604-19: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Calendar Jan 2025 - Dec 2025: From trial n pediatrics with solid tumors
Terminated
1/2
57
US
cemiplimab (monotherapy), REGN2810, Libtayo, cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Regeneron Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
05/23
05/23
CA209-8TX, NCT02960230: H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Completed
1/2
50
Europe, US
K27M peptide, Nivolumab
Sabine Mueller, MD, PhD, The V Foundation for Cancer Research, Pacific Pediatric Neuro-Oncology Consortium, Bristol-Myers Squibb
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
12/23
12/23
BLU-285-3101, NCT04773782 / 2020-005234-15: A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Active, not recruiting
1/2
37
Europe, Canada, US, RoW
avapritinib, BLU-285
Blueprint Medicines Corporation
Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
02/25
12/25
NCT01748149: Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Active, not recruiting
1
40
Canada, US
Vemurafenib, RO5185426, PLX4032
University of California, San Francisco, Genentech, Inc.
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
12/18
12/25
PNOC016, NCT03893487: Fimepinostat in Treating Brain Tumors in Children and Young Adults

Active, not recruiting
1
30
Europe, US
Fimepinostat, CUDC-907, Therapeutic Conventional Surgery
Sabine Mueller, MD, PhD, Pediatric Neuro-Oncology Consortium, Cannonball Kids' Cancer Foundation, Curis, Inc.
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
10/22
08/27
NCT02962167: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Completed
1
34
US
Modified Measles Virus, MV-NIS, Modified Measles Virus Lumbar Puncture, MV-NIS LP
Sabine Mueller, MD, PhD, No More Kids With Cancer, The Matthew Larson Foundation for Pediatric Brain Tumors, Vyriad, Inc., Mayo Clinic
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
05/23
05/23
PNOC017, NCT03749187: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Recruiting
1
78
US
PARP Inhibitor BGB-290, BGB-290, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
University of California, San Francisco, BeiGene USA, Inc.
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
06/26
07/29
PNOC025, NCT05169944: Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Completed
1
13
US
Magrolimab, Anti-CD47 Monoclonal Antibody
University of California, San Francisco, Gilead Sciences
Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor, Progressive Malignant Brain Tumor, Brain Tumor, Pediatric, Brain Tumor Adult
09/24
09/24
NCI-2021-00046, NCT04732065: ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Recruiting
1
208
Europe, US
ONC206, antagonist of dopamine receptor D2 (DRD2) /human mitochondrial caseinolytic protease P (ClpP)ClpP Agonist, DRD2 antagonist/ClpP agonist, Standard of Care Radiation Therapy, Radiation Therapy (RT), Cancer Radiotherapy, Optional Proton (1H) MR spectroscopy (MRS), MRS
Sabine Mueller, MD, PhD, Chimerix, Mithil Prasad Foundation, Storm the Heavens Fund, The ChadTough Defeat DIPG Foundation, National Cancer Institute (NCI), Dana-Farber Cancer Institute
Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm, Spinal Cord Glioma, World Health Organization (WHO) Grade III Glioma, CNS Tumor, Central Nervous System Tumor
05/27
07/27
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
House, Stacey
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
OASIS, NCT06636786: Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Not yet recruiting
2
180
US
Cyclobenzaprine HCl, TNX-102 SL, Placebo, Sugar pill
University of North Carolina, Chapel Hill, United States Department of Defense, Tonix Pharmaceuticals, Inc., Mclean Hospital, Cooper University Health Care
Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
09/25
09/25
NCT06449183: VIDAS® TBI Real Life Performance in Subjects with Mild Traumatic Brain Injury (mTBI)

Recruiting
N/A
900
US
VIDAS® TBI Test [GFAP and UCH-L1 assays]
BioMérieux
Mild Traumatic Brain Injury
06/25
11/25
Gott, Britt
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
Solon, Pam
CAMEO, NCT04076813: Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Recruiting
N/A
4000
US
Chiesi USA, Inc., Duke University
Myocardial Infarction
10/24
10/24
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
Wellen, Jason R
DHF-01-SFT-194, NCT05385952: GATT-Patch Versus TachoSil in Liver Surgery

Completed
N/A
131
Europe, US
GATT-Patch, TachoSil
GATT Technologies BV, Syneos Health
Intraoperative Bleeding, Hemorrhage, Surgical, Liver Diseases
02/24
05/24
NCT05900037: GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

Recruiting
N/A
50
US
GATT-Patch, SURGICEL® Original, Surgicel Absorbable Hemostat
GATT Technologies BV
Intraoperative Bleeding, Liver Diseases, Gallbladder Diseases, Hemorrhage, Surgical
06/24
12/24
NCT06061341: TruGraf Liver Gene Expression Serial Test

Enrolling by invitation
N/A
20
US
TruGraf®
Washington University School of Medicine, Transplant Genomics, Inc.
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
11/25
12/26
ConfIdeSLTFU, NCT05714514: Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

Recruiting
N/A
64
US
Imlifidase administered in the ConfIdeS study, IdeS, HMED-IdeS, Best available treatment administered in the ConfIdeS study
Hansa Biopharma AB
Kidney Transplantation in Highly Sensitized Patients
12/27
12/29
Altschul, David
NCT05501002: Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus

Terminated
N/A
4
US
eShunt® Implant, eShunt®, eShunt® system
CereVasc Inc, AlvaMed, Inc., Simplified Clinical Data Systems, LLC
Hydrocephalus, Hydrocephalus, Communicating
09/23
09/23
NCT05232838: US Pilot Study of the CereVasc® EShunt® System in Normal Pressure Hydrocephalus

Recruiting
N/A
50
US
eShunt Implant
CereVasc Inc, AlvaMed, Inc., Simplified Clinical Data Systems, LLC
Hydrocephalus, Normal Pressure, Hydrocephalus
01/25
01/30
NCT05071963: INSPIRE Pipeline™ Shield Post Approval Study

Active, not recruiting
N/A
246
US
Treatment of Intracranial Aneurysms
Medtronic Neurovascular Clinical Affairs
Intracranial Aneurysm
03/26
04/28
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Recruiting
N/A
180
US
WEB
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
12/25
12/29
NCT04057352: Citadel Embolization Device Study

Recruiting
N/A
150
US
Citadel Embolization Device
Stryker Neurovascular
Unruptured Wide-neck Aneurysms
06/26
06/26
SEAL™ IT, NCT05831202: SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

Recruiting
N/A
279
US
The SEAL™ Saccular Endovascular Aneurysm Lattice System
Galaxy Therapeutics INC
Intracranial Aneurysm
09/26
09/30
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Recruiting
N/A
154
US
FRED™ X™, Flow Re-Direction Endoluminal Device X
Microvention-Terumo, Inc.
Intracranial Aneurysm
09/29
11/29
Kansagra, Akash
VANTAGE, NCT04391803: EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms with the Pipeline™ Flex Embolization Device with Shield TEchnology™ (ELEVATE)

Recruiting
N/A
200
NA
Pipeline™ Flex Embolization Device with Shield Technology™, Pipeline™ Shield Device
Medtronic Neurovascular Clinical Affairs
Intracranial Aneurysm, Ruptured Aneurysm
01/26
01/27
Dirks, Annie
MUSIC-HFrEF1, NCT04703842: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Recruiting
1/2
57
US
SRD-001, Placebo
Sardocor Corp., Covance
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
12/25
12/28
Vesoulis, Zachary
NCT06637917: Pulse Oximetry Performance Comparison in Newborns

Recruiting
N/A
120
US
OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System, LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter, 1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor
Medtronic - MITG
Newborn, Birth, Preterm
02/25
02/25
Chatterjee, Arindam R
NCT05071963: INSPIRE Pipeline™ Shield Post Approval Study

Active, not recruiting
N/A
246
US
Treatment of Intracranial Aneurysms
Medtronic Neurovascular Clinical Affairs
Intracranial Aneurysm
03/26
04/28
Cortez, Justin
MUSIC-HFrEF1, NCT04703842: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Recruiting
1/2
57
US
SRD-001, Placebo
Sardocor Corp., Covance
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
12/25
12/28
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Reambonanza, Kaye
MUSIC-HFrEF1, NCT04703842: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Recruiting
1/2
57
US
SRD-001, Placebo
Sardocor Corp., Covance
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
12/25
12/28
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
Nowak, Kasia
No trials found

Download Options